Collaboration
AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs
AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry
Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines
Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership
Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs
Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals
Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration
Clinical trials, IRB, IBC, collaboration, streamlined review, multi-institutional research, regulatory efficiency, research acceleration, biosafety, human subject protection
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
Sanofi adds new inflammatory target to growing Nurix tie-up
Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI
AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts
Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration
Eli Lilly Partners with Magnet Biomedicine in $1.25B Molecular Glue Deal
Eli Lilly, Magnet Biomedicine, molecular glue, drug discovery, oncology, collaboration
Indian Biomanufacturing Alliance: Boosting National Capabilities
Indian drugmakers, biomanufacturing, trade group, collaboration, national sector growth
AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development